Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496275
Status:
COMPLETED
Last Update Posted:
2016-08-26
First Post:
2007-07-03
Brief Title:
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase I Open Label Study to Assess the Safety and Tolerability of ZD6474 ZACTIMA in Combination With Vinorelbine Navelbine or Gemcitabine Gemzar Plus Cisplatin as First Line Therapy in Patients With Locally Advanced or Metastatic Stage IIIB-IV Non Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the safety and tolerability of ZD6474 in combination withVinorelbine Navelbine or Gemcitabine Gemzar plus cisplatin as first line therapy in patients with locally advanced or metastatic Stage IIIB-IV Non Small Cell Lung Cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None